TY - JOUR
T1 - Vascular responses to local atrial natriuretic peptide infusion in man.
AU - Webb, DJ
AU - Benjamin, N.
AU - Allen, MJ
AU - Brown, J.
AU - O'Flynn, M.
AU - Cockcroft, J. R.
PY - 1988
Y1 - 1988
N2 - 1. The effect on skin and muscle blood flow of arterial infusion of atrial natriuretic peptide (ANP) directly into the forearm circulation, and on venous tone of direct infusion into a dorsal hand vein, was studied in normal subjects. 2. ANP produced a dose‐dependent increase in both skin and muscle blood flow, but at equivalent doses, produced no dilatation of noradrenaline‐preconstricted dorsal hand veins. These findings indicate that ANP acting locally, is an arterioselective dilator in the upper limb circulation in normal man. 3. Measurements of ANP in venous plasma during arterial infusion suggest marked clearance of ANP across the forearm vascular bed. Such peripheral clearance may, at least in part, account for the short plasma half‐life of this peptide. 4. The lowest dose of ANP infused was calculated to produce plasma levels similar to those found in patients with heart failure. The findings with this dose suggest that, in heart failure, circulating levels of ANP may be within a range capable of influencing peripheral vascular resistance directly. 1988 The British Pharmacological Society
AB - 1. The effect on skin and muscle blood flow of arterial infusion of atrial natriuretic peptide (ANP) directly into the forearm circulation, and on venous tone of direct infusion into a dorsal hand vein, was studied in normal subjects. 2. ANP produced a dose‐dependent increase in both skin and muscle blood flow, but at equivalent doses, produced no dilatation of noradrenaline‐preconstricted dorsal hand veins. These findings indicate that ANP acting locally, is an arterioselective dilator in the upper limb circulation in normal man. 3. Measurements of ANP in venous plasma during arterial infusion suggest marked clearance of ANP across the forearm vascular bed. Such peripheral clearance may, at least in part, account for the short plasma half‐life of this peptide. 4. The lowest dose of ANP infused was calculated to produce plasma levels similar to those found in patients with heart failure. The findings with this dose suggest that, in heart failure, circulating levels of ANP may be within a range capable of influencing peripheral vascular resistance directly. 1988 The British Pharmacological Society
UR - http://www.scopus.com/inward/record.url?scp=0023713969&partnerID=8YFLogxK
U2 - 10.1111/j.1365-2125.1988.tb05273.x
DO - 10.1111/j.1365-2125.1988.tb05273.x
M3 - Article
C2 - 2972307
AN - SCOPUS:0023713969
VL - 26
SP - 245
EP - 251
JO - British Journal of Clinical Pharmacology
JF - British Journal of Clinical Pharmacology
SN - 0306-5251
IS - 3
ER -